Revelation Biosciences Secures FDA Agreement for Streamlined Gemini Approval Pathway in Acute Kidney Injury
Key Insights
Revelation Biosciences has reached agreement with the FDA on a streamlined approval pathway for Gemini, allowing a single Phase 2/3 adaptive study design with approximately 300 patients to support a new drug application for acute kidney injury treatment.
The FDA agreed to a clinically relevant composite endpoint comprising death and/or need for dialysis, providing a clear regulatory framework for the first potential therapy targeting this significant unmet medical need.
Acute kidney injury affects more than 10% of all hospitalized patients and over 50% of ICU patients, with dialysis being the only current treatment option and Medicare spending over $10 billion annually on AKI-related costs.
Revelation Biosciences has achieved a significant regulatory milestone by securing FDA agreement on a streamlined approval pathway for Gemini, its proprietary toll-like receptor 4 (TLR4 (search)) agonist, as a treatment for acute kidney injury (AKI). The agreement establishes two critical components: a clinically relevant composite endpoint comprising death and/or need for dialysis, and confirmation that positive data from a single Phase 2/3 adaptive design study with approximately 300 patients would be sufficient for new drug application submission.
"We are grateful for the collaborative feedback from FDA on the Gemini program, which provides us a clear and expedient path forward for seeking approval of Gemini as a treatment for AKI," said James Rolke, Chief Executive Officer of Revelation Biosciences.
Adaptive Study Design Offers Strategic Advantages
The planned adaptive Phase 2/3 design will be a randomized, double-blind, placebo-controlled study comprised of two parts. Part 1 will evaluate different dosing regimens versus placebo, while Part 2 will be conducted as a Phase 3 study using the safest dosing regimen identified in Part 1. The adaptive design allows for rapid transition from Phase 2 to Phase 3 with an opportunity to sufficiently power the Phase 3 portion of the study. Data from both parts can be used in the primary and secondary endpoint analyses.
Addressing a Critical Unmet Medical Need
AKI represents a major clinical challenge, affecting more than 10% of all hospitalized patients and more than 50% of patients admitted to intensive care units. According to the University of Florida, approximately 6.8 million of the 34 million patients admitted to US hospitals annually have AKI. The condition is associated with high mortality rates, and among survivors, up to 40% later develop chronic kidney disease or progress to end-stage renal disease.
Currently, renal replacement therapy (dialysis) remains the only therapeutic option for severe AKI consequences and is required in approximately 20% of all critically ill patients. The CDC reports that Medicare alone had an annual expenditure of over $10 billion in 2015 for AKI, with spending of approximately $42,077 per patient for AKI-related costs.
Gemini's Mechanism and Development Pipeline
Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a TLR4 (search) agonist that rebalances the innate immune response. TLR4 stimulation with Gemini has demonstrated potential to treat acute and chronic diseases associated with dysregulated inflammation. The compound's potential to correct dysregulated inflammation has been demonstrated in multiple preclinical models of AKI, chronic kidney disease, and infection, as well as in two Phase 1 clinical studies.
Beyond AKI treatment (GEM-AKI), Revelation is developing Gemini for multiple indications including chronic kidney disease (GEM-CKD), reducing hyperinflammation and infection associated with severe burns (GEM-PBI), and preventing post-surgical infection (GEM-PSI).
Preparation for Clinical Execution
Over the course of 2026, Revelation will build the infrastructure required to successfully conduct the pivotal clinical study. This includes engaging a top-tier clinical research organization specializing in hospital-based renal studies, establishing an expert panel of scientific advisors, and completing the manufacture of clinical drug supply. The company is working expeditiously toward initiating the Phase 2/3 study.
The FDA agreement positions Gemini as a potential paradigm-altering treatment for patients suffering from AKI, addressing a significant unmet medical need where no approved therapies currently exist beyond supportive care and dialysis.